Advocacy

//Advocacy

Latest PSA Screening Test Guidelines from USPSTF

Here is the latest challenge to PSA test usefulness for Prostate Cancer screening in the USA.  Malecare feels you should be empowered to participate in this national health policy issue.   The U.S. Preventive Services Task Force released a new guideline, determining that the potential benefits and harms of prostate-specific antigen (PSA)-based screening in men [...]

By | 2017-10-19T10:45:48+00:00 April 11th, 2017|Advocacy|0 Comments

For Our USA Readers: Office of Men’s Health Petition and Update

Our best chance for establishing an Office of Men's Health in the USA is now, in the early days of this new administration. Our Petition at whitehouse.gov is a first and important step.   Please sign and spread the word.  This effort is entirely up to us.  We can do this! Click and Sign here: [...]

Being A “Cancer Hater” is Not Productive

My wife Wendy periodically receives Facebook requests for her to “Hate Cancer.” Yes, she does hate cancer, but she wants us all to actually be productive about what we do with our “hate.” Wendy wrote on Facebook,  "I'm not a cut and paster, and certainly not a "hater," so I have an alternative suggestion.  I just had the [...]

By | 2016-12-30T12:56:24+00:00 December 30th, 2016|Advanced Prostate Cancer, Advocacy, Uncategorized|0 Comments

In the 1990’s USA: PSA Screening Reduced Instances of Initial Diagnosis of Metastatic Prostate Cancer By 50%

Screening for early cancer detection may reduce the rate of related metastatic disease, but not always. In a published study in the New England Journal of Medicine, researchers evaluated the incidence of men having a diagnosis of advanced, metastatic prostate cancer at the initial prostate cancer diagnosis. The researchers data from the Surveillance, Epidemiology, and [...]

Politics As Usual As Congress Prepares To Not Pass The Budget – A Potential Devastating Problem for Medical Research

It is deeply troubling  to learn that Congress is considering not completing the fiscal year 2017 budget appropriations process.  Because of the normal political fighting that we still see in Washington, Congress is now considering passing a short-term or even long-term budget continuing resolution instead of the negotiated budget resolution they have worked so hard [...]

By | 2017-10-19T10:45:59+00:00 November 18th, 2016|Advanced Prostate Cancer, Advocacy, DOD, DOD PCRP, NIH, Research, Uncategorized|0 Comments

Over 20,000 Have Pledged to Boycott CVS & Caremark until they sell Cancer Drugs Again- CVS removing many cancer drugs, including Xtandi, from it’s formulary

Sign pledge to boycott CVS here: http://bit.ly/2gAJlno CVS Pharmacy will hurt many cancer patients by removing dozens of cancer treatment drugs, like leukemia drug Tasigna, prostate cancer drug Xtandi and chemotherapy treatment drug Neupogen, from their formulary, starting in 2017. CVS claims these drugs cost too much. Go ahead and tell that to my insurance [...]

By | 2016-11-03T14:10:15+00:00 November 3rd, 2016|Advanced Prostate Cancer, Advocacy, Uncategorized|0 Comments

Malecare Founder and Executive Director Darryl Mittendorf Recognized For His Major Contributions To The Prostate Cancer Community By PCRI

Malecare's Founder and Executive Director Darryl Mitteldorf was this years PCRI winner of the Harry Pinchot Award.  He is  long deserving of this award.  I would like to thank Darryl for his years and years of work and PCRI for recognizing his major contributions to our prostate cancer community. Thank you Darryl A video of [...]

Clinical Trial Results, Both Negative and Positive, Will Now Have To Be Reported In A Timely Manner!

Clinical trials are the main stream of developing and then getting necessary approvals for drugs to be able to make it to market. Drug companies, like every other company and every individual want only to have successes. We all also have egos and when there is a failure we often prefer to bury that information [...]

CVS Removes Xtandi From Its Formulary List – They Will Not Pay!

CVS Health, a major retail pharmaceutical insurer and supplier has raised some consternation and concerns and it should also raise yours. Last Tuesday, CVS rolled out their 2017 formulary list that left off the some of the world’s top-selling drugs including a vital castrate resistant prostate cancer drug. The pharmacy benefits manager removed from their [...]

Social Security Disability Insurance and Prostate Cancer

Men who have been diagnosed with advanced prostate cancer and as a result are unable to work may be able to qualify for social security disability benefits.  Under the current regulations any man who is metastatic, has late stage, and/or terminal prostate cancer should automatically meet the SSA’s eligibility requirements for disability benefits. If you [...]